IL2 and metastatic melanoma: ALT-801 is an innovative immunotherapeutic fusion protein consisting of interleukin-2 (IL-2), an approved cytokine for treatment of metastatic melanoma and renal cell carcinoma, linked to a single-chain T-cell receptor domain [22].